BTAX Stock Overview
Operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biostax Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.016 |
| 52 Week High | US$0.15 |
| 52 Week Low | US$0.011 |
| Beta | -0.037 |
| 1 Month Change | -42.18% |
| 3 Month Change | -60.25% |
| 1 Year Change | -77.30% |
| 3 Year Change | -99.39% |
| 5 Year Change | -99.68% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.6% | -2.3% | -2.6% |
| 1Y | -77.3% | -6.3% | 24.5% |
Return vs Industry: BTAX underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: BTAX underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| BTAX volatility | |
|---|---|
| BTAX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BTAX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BTAX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Noreen Griffin | www.biostaxcorp.com |
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.
Biostax Corp. Fundamentals Summary
| BTAX fundamental statistics | |
|---|---|
| Market cap | US$1.34m |
| Earnings (TTM) | -US$2.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs BTAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTAX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.22m |
| Earnings | -US$2.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -22.1% |
How did BTAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 22:49 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biostax Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ajay Tandon | SeeThruEquity, LLC |